The development of a new primary lung cancer in patients treated for metastatic renal cell carcinoma is likely underappreciated. We examine the frequency of this occurrence at our institution, report 3 cases in detail, and describe the clinical and radiographic features that help distinguish between metastatic and primary lung cancers. Introduction: The development of a second primary malignancy in a patient with a preexisting diagnosis of metastatic cancer may be easily overlooked or misattributed to progression of disease. We report 3 patients with clear-cell renal cell carcinoma (RCC) metastatic to the lungs who were subsequently diagnosed with nonesmall-cell lung cancer (NSCLC). We examined the frequency of this occurrence within our institution and report on the radiographic findings that may help distinguish between metastatic RCC and primary lung cancers. Methods: Patients who received systemic targeted therapy for metastatic RCC at our institution between January 2006 and October 2013 were identified, and the proportion and incidence rate for developing NSCLC with preexisting metastatic RCC were calculated. Results: Two percent (3/151; 95% confidence interval [CI], 0.68%-5.68%) of patients treated for metastatic RCC with systemic targeted therapies at our institution were subsequently diagnosed with NSCLC, increasing to 3.5% (3/85; 95% CI, 1.21%-9.87%) among patients with known RCC pulmonary metastasis. The incident rate for development of NSCLC in patients with metastatic RCC was 0.87 per 100 person-years (95% CI, 0.22-2.4).
Introduction
Renal cell carcinoma (RCC) is the ninth leading cause of cancer in the United States and is responsible for 14,000 deaths per year (2.4% of all cancer deaths). 1 Seventeen percent of patients present with metastatic disease. 1 The median survival of patients with metastatic kidney cancer, previously around 12 months prior to the development of targeted therapies, has steadily improved with the introduction of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGF-TKIs), mammalian target of rapamycin complex 1 (mTORC1) inhibitors, and, most recently, immune checkpoint inhibitors. [2] [3] [4] As overall survival improves, the management of patients' other medical conditions, including new primary malignancies, becomes increasingly important. Here we describe a series of 3 patients diagnosed with nonesmall-cell lung cancer (NSCLC) during treatment for metastatic RCC (mRCC), report the frequency of this occurrence within our institution, and discuss the clinical and radiographic findings that may help distinguish between metastatic disease and a new primary cancer.
Methods
After approval of the Institutional Review Board, a database of patients with mRCC treated at the University of Texas Southwestern Medical Center between January 2006 and October 2013 was generated through a search of the electronic medical record by the International Classification of Diseases, Ninth Revision diagnostic code for RCC. Patients who received treatment with a targeted agent and whose care was actively managed at the University of Texas Southwestern Medical Center during this period were included. Targeted agents included VEGF-TKIs, the anti-VEGF monoclonal antibody bevacizumab, or mTORC1 inhibitors. Charts were manually reviewed to confirm the diagnosis, and clinical information relevant to the patients' treatment and outcomes was collected. Overall survival and duration of follow-up were based on the initial diagnosis of mRCC and the date of death, or most recent clinic encounter. For patients no longer followed in our practice, the date of death was assessed through the Social Security Death Index or local obituary records. Patients were excluded if they (1) only received surgery or radiotherapy but not a targeted agent, (2) were not candidates for systemic treatment, or (3) had insufficient follow-up data available, as occurred when they were only seen for a second opinion. Patients were followed until death or the most recent database update in October 2015. The proportion of patients with mRCC and a diagnosis of lung cancer compared with those without that diagnosis was calculated, with 95% confidence intervals (CIs) determined by the Score method without continuity correction. 5 The incidence rate for lung cancer in personyears and 95% CIs were calculated by the Mid-P exact test. All calculations were performed using OpenEpi, version 3.0.
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Case 1
A 68-year-old man with a 90 pack-year smoking history and cardiovascular history notable for prior coronary artery bypass, hypertension, and multiple prior strokes was found to have with a 4. (Figure 1 ; Case 1A-B) now measuring 1.5 cm. Given the spiculated appearance on CT and the isolated nature of the progression, the concern was raised about the possibility of NSCLC. Core needle biopsy demonstrated squamous cell carcinoma (Figure 2 ; compare A and B). He was treated with stereotactic radiation (a total of 50 Gy in 5 fractions), as he was determined not to be an operative candidate owing to his cardiovascular disease and mRCC. Temsirolimus was then resumed with stable RCC disease and no evidence of the recurrent lung cancer as of February 2016.
Case 2
A 61-year-old man with a 40 pack-year history of cigarette smoking prior to quitting in 1990 and ongoing cigar smoking (3-4 per day) was diagnosed with an asymptomatic renal mass on a CT scan performed for acute diverticulitis in October 2011. Magnetic resonance imaging of the abdomen demonstrated a 10-cm upper pole left renal mass as well as a 4.1-cm contralateral right adrenal mass. CT scan of the chest demonstrated multiple pulmonary nodules (largest, 1.3 cm) and mediastinal lymphadenopathy. Biopsy of the left renal mass demonstrated ccRCC (Fuhrman Grade 3). The patient received neoadjuvant everolimus on a clinical protocol (NCT00831480), and 1 month later, had a left radical nephrectomy and bilateral adrenalectomies that revealed ccRCC in the contralateral adrenal gland. He continued everolimus postoperatively for approximately 18 months with stable disease. However, he subsequently developed Grade 2 proteinuria and gastrointestinal bleeding (later found to be secondary to a small bowel arteriovenous malformation), and everolimus was discontinued. On serial imaging, a previously identified small right upper lobe rounded nodule became spiculated, irregularly-shaped, and ultimately enlarged up to 1.3 cm in size ( Figure 1 ; Case 2A-C). The other pulmonary nodules remained unchanged or decreased in size during the same time interval. Given the isolated progression and imaging characteristics, a biopsy was obtained, which confirmed lung adenocarcinoma. The patient underwent a robotic lobectomy and ipsilateral lymph node dissection. Mediastinal and hilar lymph nodes were involved with RCC only (Figure 2 ; compare C and D). Since surgery, the patient has remained off therapy, and radiographic surveillance demonstrated only very slow progression of the remaining pulmonary nodules.
Case 3
A 67-year-old man who was never a smoker had a right radical nephrectomy in 2007 for a ccRCC (pT3aNx, Fuhrman Grade 2) and left partial nephrectomy for two pT1aNx ccRCCs (0.8-cm Fuhrman Grade 1 and 2.4-cm Fuhrman Grade 2). He had no evidence of metastatic disease on serial imaging. A serious motor vehicle accident in August 2012 resulted in a prolonged hospitalization (approximately 11 months including inpatient rehabilitation). After developing pneumonia, a CT scan of the chest demonstrated a 1.9 cm spiculated nodule in the apex of the right upper lobe with associated bronchiectasis (Figure 1 ; Case 3A-B), which at that time was attributed to the underlying infection. A CT scan 13 months later showed that the right apical nodule had increased to 2.2 cm (Figure 1 ; Case 3C-D), and there were multiple other pulmonary nodules, including a 1.2-cm pleural-based nodule in the right upper lobe. Biopsy of the more accessible 1.2-cm nodule demonstrated metastatic ccRCC ( Figure 2E ), and he started treatment with pazopanib. Over the course of the next 15 months, there was improvement in the majority of the pulmonary nodules. The largest nodule in the right apex, however, remained unchanged in size and spiculated in appearance, prompting a biopsy in February 2015, which demonstrated adenocarcinoma ( Figure 2F) . A fluorodeoxyglucose-positron emission tomography scan demonstrated uptake in bilateral mediastinal lymph nodes, which were confirmed on bronchoscopic biopsy to be involved with lung adenocarcinoma. A magnetic resonance imaging of the brain demonstrated numerous subcentimeter metastases. As his known mRCC was continuing to respond to therapy, the brain lesions were attributed to his lung adenocarcinoma. He received whole brain radiation prior to systemic chemotherapy with carboplatin and pemetrexed, but progressed after only 2 cycles. He subsequently progressed on nivolumab and passed shortly afterwards.
A summary of the 3 cases is provided in Table 1 .
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Discussion
The cases above illustrate the challenge of establishing a diagnosis of a new malignancy in a patient with a previously diagnosed metastatic cancer. Although they represent a single institution experience, they suggest that the occurrence of new lung cancers in patients with mRCC may be underreported. A review of the literature revealed only 4 previously described cases. 9, 10 The occurrence of other malignancies with RCC has been previously reported, but to our knowledge, the incidence of lung cancer in patients with RCC and pulmonary metastasis has not been documented. Patients followed after surgical resection of localized RCC do not seemingly have an increased risk of lung cancer despite an observed increased risk of bladder cancer, another smoking-related malignancy. 11, 12 However, an increased incidence of RCC following a diagnosis of lung cancer has been reported, so the relationship between these 2 malignancies remains unclear. 13 In our experience, 2% of all patients with mRCC and 3.5% of patients with lung metastasis were diagnosed with lung cancer during follow-up for their RCC diagnosis. Although smoking status was not available for our cohort as a whole, and 1 patient presented above was a nonsmoker, it would be reasonable to surmise that this figure would be even higher among patients with a smoking history. Overall, these data suggest that NSCLC in patients with RCC metastatic to the lungs is underdiagnosed clinically. There is limited literature on the radiologic appearance of pulmonary metastases from RCC. The majority of patients present with small (ie, 0.5-2 cm) nodules with well-defined smooth margins, and the number of nodules may vary from a few scattered nodules to extensive involvement of both lungs ("cannonball" metastases). A study using high-resolution CT compared the margins of the lesions with autopsy specimens and found a correlation between the growth pattern and the CT appearance.
14 Metastatic nodules with an alveolar space-filling growth pattern on histopathology exhibited smooth well-defined borders on CT. In contrast, tumors with an interstitial proliferative type growth pattern tend to exhibit irregular, poorly defined margins. In one series, 38% of metastatic lesions had smooth, well-defined margins on CT, including the one case of RCC.
14 The CT appearance of primary lung malignancies and its correlation with histopathologic characteristics is better understood. Most malignant lung nodules exhibit spiculated margins on CT corresponding to fibrosis, localized lymphangitic spread of tumor, or an infiltrative tumor growth pattern. 15 Pleural tags, such as those seen in our first and third patients, are caused by fibrotic bands usually associated with juxtacicatricial pleural retraction and are more common in malignant pulmonary lesions (58%) compared with benign nodules (27%). 15 The presence of patent bronchi within the lesion was readily apparent in our third patient and is also a CT finding more frequently associated with malignant lung lesions. 15 Nodule growth may provide additional information about the nature of the lesion. Most malignant nodules double in volume between 30 and 400 days, although faster doubling times may occur in lymphoma and metastases. 16 Similarly, infectious and inflammatory conditions may exhibit faster growing patterns. Perhaps more important is the discrepancy in the growth pattern of a single pulmonary nodule in the context of stable or decreasing metastatic lung nodules, particularly when growing nodules exhibit imaging characteristics associated with primary lung malignancies. An additional challenge in managing patients with pulmonary nodules is the lack of consistency in reporting imaging characteristics on CT reports even in patients with single lung lesions undergoing surgical resection. 17 Although an irregular, spiculated margin predicts bronchogenic carcinoma in 86% of cases, only 78% of CT reports include this feature. 17 This number is likely much lower in the case of patients with multiple pulmonary nodules and clinically suspected metastatic disease. Our results emphasize the need to specifically note the presence of pulmonary nodules with irregular and ill-defined margins in patients with mRCC to the lung in CT reports as these may represent primary lung neoplasms.
Computer-aided detection and characterization of pulmonary nodules with prediction models have been shown to be helpful in the diagnosis and presurgical evaluation of pulmonary nodules 18, 19 and may help identify these lesions. Although the standard of care is to establish a pathologic diagnosis of metastatic disease at the outset, subsequent sites of progression or metastasis are often diagnosed clinically on the basis of radiographic findings. In the case of lesions with an atypical radiographic appearance for metastatic disease, or which are progressing despite stability or regression of other metastases while on therapy, the possibility of a new primary malignancy should be considered. A history of tobacco use should also increase suspicion for the co-occurrence of smokingrelated malignancies. 20 Biopsy of a new or progressing nodule may avoid unnecessary changes in therapy, and provides the opportunity to pursue curative therapy for the early-stage cancer. Our report has several limitations. First, this is a retrospective study, and our cohort was not systematically reviewed. However, the 3 cases of lung cancer were identified by the primary oncologist (J.B.) who followed 62% of patients. Second, this report represents the experience of a single academic center that includes a large referral population and may not represent the spectrum of patients seen in general practice.
Conclusion
The occurrence of a new lung cancer in patients with mRCC is infrequently reported in the literature but in our experience is at least 2% and may be higher. Furthermore, although these cases represent a single type of secondary malignancy, we believe the principles are generalizable to any patient with metastatic disease. Patients with metastatic cancer are surviving longer, and the increased frequency of imaging tests is likely to increase the detection of new cancers. The assumption that a new or progressing lesion represents an additional focus of involvement by the same malignancy may miss the opportunity to diagnose a treatable or potentially curable new cancer.
Clinical Practice Points
The frequency of a new diagnosis of lung cancer in patients treated for mRCC at our institution was 2% and was 3.5% of those with lung metastases. Careful attention should be given to new or progressing pulmonary nodules even in patients with known RCC pulmonary metastatic disease. Radiographic findings that should raise suspicion of a new lung neoplasm include a spiculated appearance, lymphangitic spread, the presence of air bronchograms or pleural tags, or nodules that exhibit growth patterns which are discrepant from other known sites of metastatic disease.
